Dr. Alexander Paterson
MD FRCP FACP
Medical Oncologist
Department of Medical Oncology
Tom Baker Cancer Centre
1331 – 29 Street NW
Calgary, AB T2N 4N2
Email: alexpate@cancerboard.ab.ca
Current Appointments
|
Medical Oncologist |
Department of Medicine
Tom Baker Cancer Centre |
| Professor |
Departments of Medicine and Oncology, University of Calgary |
| Chair |
Alberta Provincial Breast Cancer Program |
Education and Training
|
1977 |
M.D. |
Edinburgh University
Scotland |
|
1969 |
M.B., ChB. |
Edinburgh University
Scotland |
|
1966 |
B.Sc.
|
Edinburgh University
Scotland |
Other Distinctions
|
1992-93 |
Listed in "The Best Doctors in America" and in all succeeding editions. Edited: Naifeh and Smith Published Woodward White |
| 1990 |
Special Award for Teaching
– Department of Medicine, University of Alberta |
Professional Employment and Academic Rank Record
|
1969 - 1970 |
Internship in General Surgery and General Medicine: Edinburgh hospitals |
| 1970 - 1972 |
Royal Marsden Hospital, London
Senior House Office and
Clinical Research Assistant |
| . |
Sutton General Hospital, London, Registrar |
| 1972 - 1973 |
St. Bartholomew's Hospital, London, Registrar |
| 1973 - 1975 |
Royal Marsden Hospital, London, Research Fellow |
| 1975 - 1990 |
Cross Cancer Institute and University of Alberta, Edmonton |
| 1975 |
Clinical Research Fellow |
| 1976 |
Clinical Associate |
| 1977 |
Specialist in Medical Oncology, Assistant Professor of Medicine |
| 1981 |
Senior Specialist, Medicine and Medical Oncology |
| 1983 |
Associate Professor of Medicine |
| 1990 - 2001 |
Director, Department of Medicine, Tom Baker Cancer Centre, Calgary |
| 1990 - 2001 |
Medical Oncologist, Department of Medicine, Tom Baker Cancer Centre,Calgary |
| . |
Clinical Professor, Department of Medicine, University of Calgary |
| . |
Head, Division of Medical Oncology, Department of Medicine, University of Calgary |
| . |
Head, Division of Medical and Radiation Oncology, Foothills Hospital, Calgary |
| Sept 2001 – July 2002 |
Sabbatical Leave: Clinics and Hospitals in London, UK (Royal Marsden), University of Sheffield, UK and Teaching in Medical School, Zamboanga, Philippines |
Other Professional Employment
|
1982 - 1989 |
Visiting Consultant in Internal Medicine - Inuvik and settlements, NWT, Canada |
| 1983, 1986 |
Locum Consultant (Medical Oncology), Thunder Bay, Ontario |
| 1986 - 1989 |
Staff Physician (Internal Medicine) - Clinical Teaching Unit, University of Alberta Hospital, Edmonton |
| 1990 – 2004 |
Consulting Medical Oncologist, Foothills Hospital, PLC and Rockyview Hospitals, Calgary |
Overview of Research Program
Dr. Paterson has completed clinical research in melanoma and gynecological malignancies; phase I/II and III clinical trials research in breast cancer; research on natural history of breast cancer and established and novel prognostic factors in breast cancer; patho-physiology and treatment of bone metastases; malignant hypercalcemia and its treatment; and prevention of bone metastases with bisphosphonates.
He has also performed clinical research in palliative care medicine, prevention and treatment trials in breast cancer (with US based NSABP) and previously, research in autologous bone marrow transplantation. Tumor imaging radio-pharmaceuticals have also been included in his fields of research.
He is on the Board of Directors of the NSABP and is Chair of NSABP B34 protocol and Co-chair of the SWOG/NSABP intergroup bone meatastasis prevention trial. He is Chair of several provincial and federal Medical/Scientific Advisory Committees.
He is a practicing clinical oncologist and works primarily with patients with carcinoma of the breast. He teaches the Physical Examination Course to medical students in the University of Calgary.
Currently Held Research Support
|
Agency |
Project Title |
Investigators |
Total Funding |
Term |
|
ACRI Breast Cancer Translational Group |
Breast Cancer to Bone (B2B) Metastases Program |
Friedenreich, CM
Magliocco, A
Brockton, NT
Paterson, A
Hanley, D
Vogel, H
Shemanko, C |
$1,402,890 |
2008-11 |
| AstraZeneca Canada Inc. |
. |
. |
$12,000 |
2004- present |
|
NSABP |
B-37 |
. |
. |
2005- present |
| NSABP |
B-36 |
. |
. |
2004- present |
| NSABP (NIH) |
Treatment Trials |
.
. |
approx U.S.
$100,000/pa |
1999-present |
| NSABP (NIH) |
Prevention Trials |
.
. |
approx U.S. $50,000/pa |
1999-present |
Recent Publications
ABSTRACTS
“Bone Metastases: Clinical Cancer Research (in press)”; Powles TJ, Paterson A.H.G. 2006
“Extended safety and efficacy analysis of denosumab in breast cancer patients with bone metastases without prior bisphosphonate therapy”; de Boer, R., Fan, M., Figueroa, J., Jun, S., Kinsey, A., Lipton, A., Paterson, A., Steger, G.G., Tonkin, K.S. 113 SABCS Abstract, 2006.
“Oral Clondronate (BONEFOS) in Women with Primary Breast Cancer: Effects on Bone Turnover and Skeletal Metastases” McCloskey, E., Paterson, A., Powles, T. 2006
“S0307: A phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer” Gralow, J., Paterson, A. 2006
“Adjuvant Therapy /Use of Bisphosphonates to Prevent Metastatic Disease.” Paterson, A. C.A.B. Symposium, San Antonio. December 2006.
“Cardiac Management During Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group.” Mackey, John R., Paterson, A.H.G., et al. October 2007.
“Phase II study of denosumab in breast cancer patients with bone metastases naive to intravenous bisphosphonate therapy : extended efficacy and safety analysis.” Lipton, A., deBoer, R., Paterson, A., et al. ASCO Breast Cancer Symposium. September 2007.
JOURNAL PUBLICATIONS
Paterson, A.H.G. “Treatment of a Patient With Estrogen Receptor-Positive/Progesterone Receptor-Negative Early-Stage Breast Cancer With Borderline Osteopenia.” Oncology Consultations, Volume 3, Number 15 2007.
Paterson, A.H.G., et al. « Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients with Breast Cancer-Related Bone Metastases.” Journal of Clinical Oncology.Volume 25, Number 28 2007.
Mackey, J.R., Clemons, M., Paterson, A.H.G., et al. “Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group.” Current Oncology. Vol. 15, No.1. 2008.
Paterson, A.H.G. “Current status of adjuvant bisphosphonates in operable breast cancer.” Breast Cancer Online. Cambridge University Press, 11(4). 2008.
Paterson, A., McCloskey, E., Redzepovic, J., Ott, I., Gust, R. “Cost-effectiveness of Oral Clodronate Compared with Oral Ibandronate, Intravenous Zoledronate or Intravenous Pamidronate in Breast Cancer Patients.” Journal of International Medical Research. Field House Publishing, Vol. 36, No. 3. May/June 2008.
Paterson, A.H.G. “Treatment of a Patient With Estrogen Receptor-Positive/Progesterone Receptor-Negative Early-Stage Breast Cancer With Borderline Osteopenia.” Oncology Consultations, Volume 3, Number 15 2007.
Paterson, A.H.G., et al. « Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients with Breast Cancer-Related Bone Metastases.” Journal of Clinical Oncology.Volume 25, Number 28 2007.
Aapro, M., Abrahamsson, P.A., Paterson, A.H.G., et al. “Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.” Annals of Oncology. September 2008. 19(3):420-432.